Navigation Links
ACT Interim Chairman and CEO Gary Rabin to Present at World Stem Cells & Regenerative Medicine Congress in London

MARLBOROUGH, Mass., May 5, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that interim chairman and CEO Gary Rabin will be presenting at the World Stem Cells & Regenerative Medicine Congress, May 9-11, in London.

Mr. Rabin's presentation, titled "Using ESC-Derived RPE Cells for Dry AMD and Stargardt's Disease," will be given on Monday, May 9.  In it, he will provide an update on ACT's forthcoming human clinical trials for Dry Age-Related Macular Degeneration (Dry AMD) and Stargardt's disease.

ACT recently announced Institutional Review Board (IRB) approval of its Phase 1/2 clinical trials for the treatment of macular degeneration with human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells to be conducted at UCLA's Jules Stein Eye Institute.

About SMD, Dry AMD and Degenerative Diseases of the Retina

Stargardt's Macular Dystrophy (SMD) is one of the most common forms of macular degeneration in the world.  SMD causes progressive vision loss, usually starting in children between 10 to 20 years of age.  Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium or RPE cell layer.

Degenerative diseases of the retina are among the most common causes of untreatable blindness in the world.  As many as thirty million people in the United States and Europe suffer from macular degeneration, which represents a $25-30 billion worldwide market that has yet to be effectively addressed.  Approximately 10% of people ages 66 to 74 will have symptoms of macular degeneration, the vast majority the "dry" form of AMD – which is currently untreatable. The prevalence increases to 30% in patients 75 to 85 years of age.  

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-K for the year ended December 31, 2010.  Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company's clinical trials will be successful.


CEOcast, Inc., James Young, 212-732-4300

ACT Corporate Communications, Bill Douglass, 646-450-3615
Russo Partners, Martina Schwarzkopf, Ph.D., 212-845-4292

SOURCE Advanced Cell Technology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ACT Interim Chairman and CEO Gary Rabin to Present at BIO-Europe Spring 2011 Conference
2. YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
3. Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD
4. Aeterna Zentaris Announces Orphan Drug AEZS-130 (Macimorelin, Solorel(TM)) Interim Phase 3 Data Analysis Shows Potential for 2011 Filing as Oral Diagnostic Test for Adult Growth Hormone Deficiency (AGHD)
5. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
6. Former Fujifilm Medical Systems USA Executive John J. Weber Agrees to Join Regenicin™ as a Member of Its Board of Directors and Interim CFO
7. Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing
8. AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimers Vaccine Candidate AD02 into Clinical Phase II Testing
9. Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
10. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
11. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 September 2009
Post Your Comments:
(Date:10/12/2015)... MARIETTA, Ga. , Oct.12, 2015  MiMedx Group, ... company utilizing human amniotic tissue and patent-protected processes to ... Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and ... tam complaint which had been filed against the Company ... Parker H. Petit , Chairman and CEO, stated, "As ...
(Date:10/12/2015)... de octubre de 2015 El 8 de ... un récord en el congreso con su declaración acerca ... International Plasma Awareness Week (IPAW), que se celebrará del ... por la Plasma Protein Therapeutics Association (PPTA) ... , Aumentar la concienciación mundial acerca de la ...
(Date:10/12/2015)... , October 12, 2015 ... print version for enriched online experience --> ... alternative to print version for enriched online experience ... multi media alternative to print version for enriched ... provider of scientific, technical and medical information products and ...
(Date:10/12/2015)... ... 2015 , ... LifeTrak , a leader in consumer fitness, heart rate ... amphibious fitness tracker that seeks to meet the needs of multi-sport athletes. Zoom is ... monitoring both in water and on land, making it the only fitness tracker ...
Breaking Biology Technology:
(Date:9/24/2015)... , September 24, 2015 ... 25 september 2015 Kerv ( ... digitala finanstjänster, lanserar idag världens första kontaktlösa ... samla in 77 000 GBP för massproduktion ... ) , Kerv-bärare ...
(Date:9/10/2015)... -- Report Details The global wearable technology ... expectations of revenues, consumer adoption and even technological advances. ... wearables begin to achieve that mass market acceptance that ... is the entrance of Apple to the SmartWatches market, ... the overall size of the wearable technology market. ...
(Date:9/9/2015)... , Sept. 9, 2015  NuData Security announced ... solution-based milestones, furthering the company,s commitment to protecting ... fraud. NuData Security,s online fraud detection ... company,s growth cycle. The product combines continual analysis ... good user behavior from fraudulent behavior, allowing the ...
Breaking Biology News(10 mins):